Quidel

News Release

Printer Friendly Version View printer-friendly version << Back
August 29, 2002 at 7:04 AM EDT

Quidel Receives Additional Patent Protection On Layered Thin Film Technology

Patent Covers Broad Potential in Dried External Controls

SAN DIEGO, Aug 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- Quidel Corporation (Nasdaq: QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, today announced receipt of additional patent protection for its LTF(TM) (Layered Thin Film) technology. The recently allowed U.S. patent covers broad potential for use in dried external positive and/or negative controls for many types of diagnostic tests and supplements the built-in, specimen-activated procedural controls featured on the Company's recently introduced QuickVue(R) Advance tests.

The newly patented dried controls are convenient, easy-to-use, inexpensive and stable at room temperature, offering advantages over many traditional external liquid controls currently available. These self-contained dried controls do not require refrigeration, and eliminate the inconvenience and expense of lyophilized control solutions. First-time users are able to use the dried controls and rapidly learn to distinguish a positive from a negative test result immediately prior to using the test device on a clinical specimen. Since these dried controls are produced at low cost and high speed, they can either be included directly on the LTF(TM) test or included within a standard package of test devices.

"As the leading provider of POC diagnostics tests, Quidel has made significant investments in time and dollars to provide this specialized control for labs and other POC providers," said S. Wayne Kay, Quidel's president and chief executive officer. "The broad potential application of this patent serves not only to further strengthen our LTF(TM) technology, but also opens up the potential for out-licensing opportunities."

About LTF(TM) (Layered Thin Film) Technology

This year, Quidel Corporation, the leading manufacturer of rapid point-of- care (POC) tests for the physician's office, introduced the revolutionary new LTF(TM) (layered thin film) technology. An easy to read, extremely precise test platform, LTF(TM) tests are as small and as thin as a credit card. The first two of several products in development are being marketed under the QuickVue(R) Advance brand: pH and Amines test and G. vaginalis test.

About Quidel

Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point- of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, chlamydia, infectious mononucleosis and bacterial vaginosis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at http://www.quidel.com .

This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results and performance of Quidel's products, such that actual results and performance may differ materially. If Quidel's products fail to perform as expected, or if there is lower consumer demand for these products than expected, Quidel's financial condition and operating results may be materially and adversely affected. Quidel's financial condition and operating results may also be materially and adversely affected by a number of other factors, including, without limitation, seasonality, adverse changes in competitive and economic conditions, actions by the Company's distributors, manufacturing and production delays or difficulties and adverse actions or delays in product reviews by the FDA. Please see the discussion of these and other factors in Quidel's annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. For more information, please visit Quidel's Web site at http://www.quidel.com .

CONTACT:
media, Bea Evangelista of Euro RSCG Middleberg,
+1-212-699-2503, bea.evangelista@eurorscg.com, for Quidel Corporation; or
investors, Ina McGuinness of Lippert/Heilshorn, +1-310-691-7105,
imcguinness@lhai.com, for Quidel Corporation; or Paul E. Landers, Vice
President & Chief Financial Officer of Quidel Corporation, +1-858-552-7962